Efficacy, safety and cost of new cardiovascular drugs: A survey

European Journal of Clinical Pharmacology

Volumn 59, Issue 8-9, 2003, Pages 701-706

  Garattini, Silvio ^a   Bertele', Vittorio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cardiovascular drugs; Drug regulation; European market

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DESULFATOHIRUDIN; DOFETILIDE; ENOXAPARIN; EPTIFIBATIDE; FIBRIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IRBESARTAN; KINZALCOMB; LEPIRUDIN; PLASMIN; RETEPLASE; TELMISARTAN; TENECTEPLASE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; BLEEDING; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG MIXTURE; ESSENTIAL HYPERTENSION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; LONG QT SYNDROME; NAUSEA; NEUTROPENIA; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TORSADE DES POINTES; TOTAL HIP PROSTHESIS; VOMITING;

CARDIOVASCULAR AGENTS; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION;

EID: 0345598086     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0634-y     Document Type: Review

References (22)

1. Garattini S, Bertele' V (2002) Efficacy, safety, and cost of new anticancer drugs. BMJ 325:269-271
2. Garattini S, Bertele' V (2003) Efficacy, safety, and cost of new drugs acting on central nervous system. Eur J Clin Pharmacol 59:79-84
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335:827-838
4. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 355:1955-1964
5. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ, for The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857-865
6. McClellan KJ, Markham A (1999) Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs 58:1043-1059
7. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
8. Born GVR, Collins R (1997) Aspirin versus clopidogrel: the wrong question? Lancet 349:806-807
9. Topol EJ, Byzova TV, Plow EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353:227-231
10. PURSUIT investigators (1998) Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina - receptor suppression using integrilin therapy. N Engl J Med 339:436-443
11. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851
12. Eriksson BI, Wille-Jørgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329-1335
13. Eriksson BE, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298-1304
14. Bauer KA, Eriksson BE, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305-1310
15. Lassen MR (2000) The EPHESUS Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 96:490a
16. Turpie G (2000) The PENTATHLON 2000 Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 96:491a
17. Diuguid DL (2001) Choosing a parenteral anticoagulant agent. N Engl J Med 345:1340-1342
18. International Joint Efficacy Comparison of Thrombolytics (1995) Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 346:329-333
19. The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO-III) investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118-1123
20. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) investigators (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716-722
21. Bertele' V, Torri V, Garattini S (1999) Inconclusive messages from equivalence trials in thrombolysis. Heart 81:675-676
22. Yusuf S (2002) Two decades of progress in preventing vascular disease. Lancet 360:2-3